Dihydroboldenone cypionate (DHB-C) 50 mg/mL

Basic Info

CAS Number	Unconfirmed
Active Ingredient	Dihydroboldenone (1-testosterone / DHB) cypionate
Dosage Form	Oil injection
Specification & Packaging	Strength: 50 mg/mL Pack: 10 × 1 mL ampoules/vials Group: 01 Item No.: 2

Storage & Common Excipients

Storage Conditions	Tightly closed, protected from light, 15–25 °C (typical oil-injectable condition). Confirm before refrigerating, as cooling can cause crystallisation; follow the label
Common Excipients	Typical oil formulation: castor/peanut/sesame oil, polysorbate 80, benzyl alcohol, benzyl benzoate, edetate disodium; confirm against supplier COA

Product Introduction

The cypionate ester of the 5α-reduced form of boldenone. **Not approved for human use by any regulatory authority**; a research anabolic steroid. The source file lists the CAS as unconfirmed, and this check found a direct conflict in public databases (65-06-5 is the CAS of testosterone cypionate, while 15029-96-1 corresponds to free dihydroboldenone), so no authoritative CAS can be confirmed for this ester.

Therapeutic Use

No approved indication. Research use includes pharmacokinetic and androgen-receptor binding studies of non-aromatising long-acting anabolic steroids

Mode of Action

Higher androgen-receptor affinity than testosterone itself; 5α-reduced and therefore not readily aromatised to oestrogens, so oestrogenic effects are theoretically lower; the cypionate ester gives roughly 7–10 days of release

Administration & Monitoring

Use by compliant research institutions only; in animal studies monitor serum testosterone, DHT, oestradiol, liver function and lipid profile

Important Safety Information

Research compound, not a clinical medicine; non-medical use is unlawful and hazardous; no approved human safety data exist

Adverse Reactions

Expected to behave as an anabolic steroid: androgenic features, acne, hirsutism, muscular hypertrophy, alopecia; injection-site pain and induration (common with viscous oil solutions); raised liver enzymes and dyslipidaemia. No product-specific human adverse-reaction data exist

Important Risks

Cardiovascular risk (polycythaemia, left-ventricular hypertrophy), reproductive suppression (oligospermia/azoospermia), raised haemoglobin; effect on the prostate not established

Contraindications

No official contraindication information. By principle: pregnancy and lactation; known or suspected prostate/breast cancer; paediatric or adolescent use; severe cardiac, hepatic or renal impairment

Special Populations

Contraindicated in children and adolescents; contraindicated in pregnancy and lactation; use with caution in older males with prostate and cardiovascular assessment

Usage Limitations

Strictly prohibited for human bodybuilding or competitive sport (WADA-prohibited); handling limited to compliant research settings

Anti-Doping Testing

WADA Prohibited List S1.1; targets dihydroboldenone/1-testosterone, detectable by GC-MS/MS and LC-MS/MS; ester prodrugs substantially extend the detection window

Product Quality Testing

Identification (HPLC + MS), assay/content uniformity, related substances, clarity and particulate matter, fill volume, sterility and endotoxin, residual solvents (e.g. benzyl alcohol), stability; COA recommended

Source & Verification Note

Source file marked "unconfirmed". This check found conflicting public records (65-06-5 is testosterone cypionate; 15029-96-1 is free dihydroboldenone). **No authoritative CAS can be confirmed; left as to-be-confirmed.**